X-ray price war in the US hits Nycomed Amersham's half-year
This article was originally published in Clinica
Price pressures in European X-ray markets, together with lower prices in the US X-ray contrast media markets, depressed Nycomed Amersham's results for the first six months of this year.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.